Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN5 | P54829 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7413072 | 0.74 | PGK1 (0.36) | — | |
| SCHEMBL698715 | 0.71 | LPAR1 (0.37) | — | |
| SCHEMBL14243647 | 0.69 | — | — | |
| SCHEMBL11031855 | 0.68 | KDM4E (0.31) | — | |
| Ammonia Solution, Strong SCHEMBL8988620 | 0.67 | — | — | |
| SCHEMBL8662380 | 0.67 | LPAR1 (0.31) | — | |
| SCHEMBL1377737 | 0.66 | MMP2 (0.43) | — | |
| SCHEMBL27541430 | 0.64 | CA2 (0.32) | — | |
| SCHEMBL9254732 | 0.64 | MAPK1 (0.46) | — | |
| SCHEMBL3361729 | 0.63 | FDPS (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107820499-B | Antiviral compounds, process for their preparation, and their use for the treatment of viral infections | 鲁汶大学研究与开发部 | 2022-11-11 | — | — | CN | disclosed |
| US-10087209-B2 | Antiviral compounds, a process for their preparation, and their use for treating viral infections | KU LEUVEN RESEARCH & DEVELOPMENT (BE) | 2018-10-02 | — | — | US | disclosed |
| US-20180105552-A1 | NOVEL ANTIVIRAL COMPOUNDS, A PROCESS FOR THEIR PREPARATION, AND THEIR USE FOR TREATING VIRAL INFECTIONS | KU LEUVEN RESEARCH & DEVELOPMENT (BE) | 2018-04-19 | — | — | US | disclosed |
| WO-2016174081-A1 | NOVEL ANTIVIRAL COMPOUNDS, A PROCESS FOR THEIR PREPARATION, AND THEIR USE FOR TREATING VIRAL INFECTIONS | KU LEUVEN RESEARCH & DEVELOPMENT (BE) | 2016-11-03 | — | — | WO | disclosed |
| US-20090131372-A1 | PHOSPHONATE ANALOGS FOR TREATING METABOLIC DISEASES | CHEN JAMES M | 2009-05-21 | — | — | US | disclosed |
| US-7407965-B2 | Phosphonate analogs for treating metabolic diseases | GILEAD SCIENCES, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-20050227947-A1 | Phosphonate analogs for treating metabolic diseases | GILEAD SCIENCES, INC. | 2005-10-13 | — | — | US | disclosed |
| WO-2004096237-A2 | PHOSPHONATE ANALOGS FOR TREATING METABOLIC DISEASES | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| US-5952327-A | NEUTRAL ENDOPEPTIDASE INHIBITORS; TREATMENT OF CARDIOVASCULAR DISORDERS | SOLVAY PHARMACEUTICALS GMBH (DE) | 1999-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227947-A1 | Phosphonate analogs for treating metabolic diseases | PHOSPHO1, G6PC1, PC | PTPN5 1340/4885 |
| US-20180105552-A1 | NOVEL ANTIVIRAL COMPOUNDS, A PROCESS FOR THEIR PREPARATION, AND THEIR USE FOR TREATING VIRAL INFECTIONS | TYMP, MTAP, PNP | PTPN5 1821/4885 |
| US-20090131372-A1 | PHOSPHONATE ANALOGS FOR TREATING METABOLIC DISEASES | PHOSPHO1, G6PC1, PC | PTPN5 1340/4885 |
| US-10087209-B2 | Antiviral compounds, a process for their preparation, and their use for treating viral infections | TYMP, PNP, MTAP | PTPN5 1810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.